Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vilya logo — Compute Beyond Nature

Vilya

Compute Beyond Nature

Founded 2022 United States Seattle, United States 47 employees Series A Total: $71.00M Biotechnology, Pharmaceutical

General Information

Company Name Vilya
Founded Year 2022
Location United States Seattle, United States
Employees 47
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, Platform, B2B2C
Revenue Model Licensing, Product Sales
Offices as of Nov 2026
Seattle, United States South San Francisco, United States
Social

BounceWatch is an independent company data service, not affiliated with Vilya. To contact Vilya, visit vilya.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vilya compare?

A PDF of Vilya and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vilya soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vilya

Vilya, founded in 2022, is a pioneering entity in the Biotechnology and Pharmaceutical sectors, headquartered in the United States. Operating under the slogan "Compute Beyond Nature," the company is transforming how new medicines are developed by venturing into unexplored chemical realms.

Co-founded by a team from the Institute of Protein Design under the guidance of David Baker, Ph.D., and supported by ARCH Venture Partners, Vilya leverages advanced computational techniques to design molecular structures not found in nature. Their goal is to create a novel class of medicines that can precisely target disease biology, thereby offering new avenues for curing diseases.

The company's credibility and potential have been reinforced by a significant $21.00M Series A investment, closed on June 1, 2024. This funding round was backed by notable ventures including Madrona, ARCH Venture Partners, Menlo Ventures, Altitude Life Sciences, LifeForce Capital, and nVentures.

Business keywords: Computational Biotechnology, Cyclic Peptides, Medical Innovation, Molecular Design, Disease Targeting, Protein Design, Advanced Computing, Machine Learning in Biotech, Medicinal Chemistry, Biological Sciences, Drug Discovery, Chemical Space Exploration, Life Sciences R&D, Biomedical Research

Services & Products

Design of novel macrocycles using AI
Oral bioavailable drug development
Precision therapeutic molecule design

Target Customers

Pharmaceutical companies Biotech researchers Medical professionals focused on untreatable diseases Investors and partners in innovative medicine

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $21.00M 6
Madrona Arch Venture Partners Menlo Ventures
Madrona, Arch Venture Partners +4
01 Jun 2024
Series A $50.00M 1
Arch Venture Partners
Arch Venture Partners
01 Aug 2022
Spinout Undisclosed 1
University of Washington Institute for Protein Design
01 Jan 2022

Latest News

View All
Revolutionizing Antibody Design with AI: Why We’re Backing Chai Discovery — Menlovc.com
Revolutionizing Antibody Design with AI: Why We’re Backing Chai Discovery
Menlovc.com Aug 06, 2025

Vilya Alternatives & Competitors

View All Alternatives
Vilya vs
1200 Pharma
1200 Pharma United States

We leverage our breakthrough chemistry, cutting edge computation & data-rich models to accelerate dr...

Venture round
32 employees
Biotechnology, Health Care
Compare Vilya vs 1200 Pharma
Vilya vs
Numerate
Numerate

Elevating Drug Discovery Through Advanced Computational Innovation

Series C
5 employees
AI, Biotechnology
Vilya vs
iktos
iktos France

Artificial intelligence for new drug design

Series A
62 employees
AI, Biotechnology
Also compare with: Vilya vs Septerna Septerna View all alternatives

FAQ About Vilya

Compute Beyond Nature
Vilya was founded in 2022.
Vilya is headquartered in Seattle, United States. As of Nov 2026, it also has offices in South San Francisco, United States.
Vilya operates in Biotechnology and Pharmaceutical. Its work centres on Computational Biotechnology, Cyclic Peptides, Medical Innovation and Molecular Design. Its customers include Pharmaceutical companies, Biotech researchers and Medical professionals focused on untreatable diseases.
Vilya has a B2B, Platform and B2B2C business model. Its revenue comes from Licensing and Product Sales.
Vilya has approximately 47 employees.
Vilya has completed 3 funding rounds, raising a total of $71.00M. The latest funding stage is Series A.
Vilya offers: Design of novel macrocycles using AI, Oral bioavailable drug development, Precision therapeutic molecule design.
Top alternatives and competitors to Vilya include 1200 Pharma, Numerate, iktos, SyntheticGestalt, PROTEINA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vilya and 1200 Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vilya, https://bouncewatch.com/company/vilya, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout